These findings highlight the potential of 2,4-diHB as a therapeutic agent for ADCK4-deficient nephropathies, offering a promising approach to stabilizing podocytes and preserving kidney function in patients with SRNS. The gene discussed is COQ8B; the disease is Nephropathy.